Catalyst Q1 2026 revenue $149.4M; FIRDAPSE up 18%, AGAMREE up 67% YoY

CATALYST PHARMACEUTICALS, INC.

2026-Q1 EPS reported $0.50 revenue$149,390,000

Product revenue net $149.3M for Q1 2026, up 5.6% YoY from $141.4M.
FIRDAPSE net revenue $98.9M (+18% YoY); AGAMREE $36.7M (+67%); FYCOMPA $13.8M (-61%).
GAAP net income $63.7M ($0.52 basic EPS); non-GAAP net income $100.3M ($0.82 basic EPS).
Cash & equivalents $755.9M at March 31, 2026, up from $709.2M; no funded debt.
No forward guidance or updated FY2026 outlook provided in the release.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.